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Previous studies ofHLAmatching in unrelated donor (URD) trans-
plantation have focused largely on patients with leukemia. The effect
of donor-recipient mismatching in patients with nonmalignant disor-
ders (NMD) may differ and remains poorly defined.
We analyzed data from theCIBMTRdatabase on 667URD trans-
plants performed for a NMD between 1995 and 2007. The initial
analysis was restricted to donor-recipient pairs that were allele
matched at the A, B, C and DRB1 loci (375), matched at 7/8 alleles
(191) or matched at 6/8 alleles (101). The median patient age was 9
years and did not differ between the three groups. The distribution
of the types of NMD was similar in the three groups.
Across all groups, the most common were severe aplastic anemia
(54%), immunodeficiencies (18%), inborn errors of metabolism (14%)
andhistiocytic disorders (10%).Transplants involving 8/8matchedpairs
were more likely to have been performed after 2001 (72% vs. 60% vs.
36%, p\ 0.0001), to involve a Caucasian recipient (78% vs. 68% vs.
62%, p 5 0.009) and to involve donor and recipients who were both
CMV seronegative (39% vs. 24% vs. 27%, P 5 0.004), respectively.
Theunadjustedoverall survival atfiveyearswas65%,57%and47%after
transplants involving 8/8, 7/8 and 6/8 matches (p5 0.004). The cumu-
lative incidence of grade 2-4 acute GVHD was 43, 40 and 44% (p 5
0.76) at 100 days and of chronic GVHD was 32, 29, and 30% (p 5
0.82) at 2 years. The multivariate analyses demonstrated an association
between degree of mismatch and mortality. The hazard ratio for 7/8
matched transplants was 1.31 (95% CI, 0.98-1.75, p 5 0.066) and for
6/8 matched transplants was 1.75 (1.25-2.45, p5 0.0012) compared to
8/8 matched pairs. No association between degree of mismatching and
acuteGVHDII-IV, acuteGVHD III-IV or chronicGVHDwas noted.
Our results underscore the importance of HLAmatching in trans-
plants for NMD. They also suggest that the effects of mismatching
are mediated by a complication other than GVHD. Graft failure
may be an important cause of treatment failure; we are currently col-
lecting the chimerism data necessary to analyze this outcome.
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THE RISK FACTORS FOR SURVIVAL IN HAPLOIDENTICAL HEMATOPOI-
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To determine the risk factors for survival in haploidentical hemato-
poietic stem cell transplantation (haplo-HSCT), the clinical outcomes
of a large series of haplo-HSCTinourhospital are analyzed. FromApril
2002 to April 2010, consecutive 440 patients with hematological malig-
nancies who underwent haplo-HSCT were included. The median age
was 23 (3-59) years old. The diagnosis included AML (39.8%), ALL
(35.9%), MDS (3.6%), CML (16.1%), and others (4.6%). Transplants
at CR1 or CML-CP1,$CR2 or CML-CP2/AP, and advanced disease
(refractory/relapsed acute leukemia or CML-BC) were 33.4%, 40.9%
and 25.7%. HLA mismatched at 1, 2, 3 loci was 13.2 %, 27.5%,
59.3%, respectively. All patients received unmanipulated combined
marrow and peripheral blood for transplant after BUCy2/CyTBI plusATGconditioning.Prophylaxis and treatmentofGVHDwere reported
previously (Dao-Pei Lu et al., Blood 2006; 107:3065). Steady hemato-
poietic reconstitution was seen in 98.6% of recipients. The cumulative
incidences of grade II to IV acute GVHD and chronic GVHD were
32.6%, 61.3%. With the median follow-up of 32 (3-99) months, 2-
year overall survival (OS) rates were 76.1%, 59.8% and 31.1% in CR1
orCML-CP1,$CR2 or CML-CP2/AP and advanced disease, respec-
tively.Univariate analysis showedthat lowerCD341 cell infused (\2.85
 106/kg) has much poor OS compared with higher CD341 cell trans-
planted (. 2.85 106/kg) (p5 0.006); Transplants in sex-mismatched
donor-recipient pair has remarkable worse 2-year OS (37.6% in male
donor to female recipient, 55.3% in female donor to male recipient)
compared with sex-matched transplants (65.6%) (p5 0.000). Multivar-
iate analysis showed that disease status before transplant,CD341 cell in-
fused and sex-matched or not between donor and recipient were pivotal
impact factors on survival. In conclusion, our clinical results froma large
series of haplo-HSCT demonstrate that advanced disease, low CD341
cell infused, and sex-mismatched between donor and recipient are the
risk factors for OS.IMMUNE RECONSTITUTION58
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Background: Umbilical cord blood (UCB) transplantation is associ-
ated with delayed hematopoietic and immune reconstitution (Sza-
bolcs/Cairo et al Seminars in Hematology 2010). NK cells play
important roles in both innate and adaptive immunity and are charac-
terized as a CD561 cell population (Shereck/Cairo et al PBC 2007).
We demonstrated the ability to ex-vivo expand CBMNC into various
phenotypesofCD561dim andCD561brightNK(totally 60%) andNKT
cells (40%)with profound in vitro and in vivo cytotoxicity against hema-
tologicalmalignancies (Ayello/CairoBBMT2006&Exp.Hematology
2009). Our genomic studies showed highly expressed CD34 and other
genes in CB vs PB CD561dim NK cells (Day/Cairo et al ASH 2010).
Objective: We sought to determine proteomic signatures in CB vs
PB CD561dim NK cells.
Methods: CB NK CD561161dim cells (94% enrichment) isolated
using a standard kit (Miltenyi Biotec). Proteomic studies were per-
formed by LC MS/MS with iTRAQ labeling and analyzed with
SEQUEST, ProteinProphet, and INTERACT. Proteomic path-
ways were analyzed using Ingenuity pathway analysis (IPA). CY5
and CY3 two-color ECL Plex fluorescence Western blotting (WB)
images were scanned with TYPHOON and analyzed using Image-
Quant to validate the proteomic data.
Results: CB vs PB CD561dim cells significantly over expressed 35 pro-
teins, including CELSR1 (25.0F), BLM (25.0F), BDNF (20.0F), PKD1
(16.7F), NOTCH2 (16.7F), BIRC2 (12.5F), AIFM1 (12.5F), EP400
(5.3F), PBX1 (3.9F), SIRT2 (2.9F), LETM1 (2.9F), and ESR2 (2.4F).
WB results validated the proteomic results. IPA results indicate that top
molecular functions of these proteins include gene expression (p\ 0.03),
apoptosis (p\ 0.03), cellular development (p\ 0.03). CELSR1, BDNF,
ESR2,TAGLN,SIRT2,PBX1, andAIFM1 togetherwithHOXvariants,
FOXA1,FOS,andSP1facilitateacelldevelopmentalnetwork.NOTCH2,
BDNF, PKD1, LETM1, AIFM1, SIRT2, ESR2, and EP400 together
with cMYC, NFkB, TP53 build a network toward apoptosis.
Conclusion: Considering that CB is of fetal origin, it is not surprising
that CB CD561dim populations may be earlier in development (pro-
NK) with over expression of CD34 gene and CELSR1, BLM and
BDNF early developmental stage proteins. Decrease in CB vs PB NK
cytotoxicitymaybe in part secondary to increase programmed cell death
(apoptosis). Our CB proteomic signatures suggest a possible explana-
tion for immaturity of CB innate and adaptive immunity. (The first
two authors contribute equally).
